The NF-κB pathway blockade along with low expression of programmed cell death ligand 1 (PD-L1) via interleukin-1 receptor-associated kinase 1/4 (IRAK1/4) and imatinib, has been reported to repress CML-LSCs. Here, NFKB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.